Calciphylaxis Clinical Trial
Official title:
Evaluation of Efficacy of Lanthanum Carbonate (Fosrenol) in Patients With Calciphylaxis
The research question and primary aim is to determine if lanthanum carbonate is effective in treating calciphylaxis by measurement of complete or partial remission of skin lesions. Secondary endpoints will be measured to determine if lanthanum carbonate can lower calcium-phosphorus product levels, intact PTH and mortality. Albumin levels will be measured as a marker of nutritional status and inflammation.
Calciphylaxis or calcific uremic arteriolopathy is an infrequently occurring although debilitating vasculopathy seen primarily in patients with end stage renal disease (ESRD) which almost always affects the skin. It has a prevalence rate ~4 % in long term hemodialysis patients, with 1-year survival of 45% and an 8-fold risk of death as compared to the general dialysis population. (Surgery 1997;122:1083-1089, Kidney Int 2001;60:324-332). Despite being described in the literature for over 100 years, there has been no proven effective therapy. Lanthanum carbonate (FOSRENOL®) is a potent non-aluminum, non-calcium phosphate binder that was approved for use to reduce serum phosphate levels in patients with end stage renal disease. Since the proposed etiologic mechanism of injury and vascular calcification of calciphylaxis is predominantly hyperphosphatemia, elevated serum PTH, and hypercalcemia, FOSRENOL® would be an ideal pharmacologic agent to utilize in this extremely enigmatic disease (Dermatol Clin. 2008 Oct;26(4):557-68). Furthermore, a recent case report demonstrated a significant improvement in laboratory parameters and calciphylaxis skin lesions with the use of FOSRENOL® (WMJ. 2008 Nov;107(7):335-8). The primary hypothesis is that since calciphylaxis represents the ultimate sequelae of metastatic vascular calcification predominantly involving hyperphosphatemia, elevated serum PTH, and hypercalcemia, FOSRENOL® will be efficacious in its treatment. ;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01578382 -
Pathophysiology of Martorell Hypertensive Ischemic Leg Ulcer (HYTILU)
|
||
| Active, not recruiting |
NCT04592640 -
Stem Cells for Uremic Calciphylaxis Patients
|
N/A | |
| Terminated |
NCT03319914 -
Observational Follow-up to ST-001 Calciphylaxis Pain Treatment With Intravenous Sodium Thiosulfate
|
||
| Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
| Terminated |
NCT03150420 -
A Phase 3 Clinical Trial of Intravenous Sodium Thiosulfate in Acute Calciphylaxis Patients
|
Phase 3 | |
| Completed |
NCT02790073 -
Phase 2 Study With SNF472 in Calciphylaxis Patients
|
Phase 2 | |
| Recruiting |
NCT03146793 -
The Early Administration of Sodium Thiosulfate Should Help to Reduce the Mortality of Dialysis Patients With Calciphylaxis, From a National Cohort
|
N/A | |
| Completed |
NCT02278692 -
Evaluation of Vitamin K Supplementation for Calcific Uremic Arteriolopathy
|
N/A | |
| Completed |
NCT02854046 -
Calciphylaxis : Population, Risk Factors, Diagnostic Practice, Therapeutic and Outcome
|
||
| Terminated |
NCT02527213 -
Randomized Double Blind Placebo Controlled Trial of Sodium Thiosulfate for the Treatment of Pain Associated With Calcific Uremic Arteriolopath
|
Phase 3 | |
| Recruiting |
NCT03032835 -
Partners Calciphylaxis Biobank
|
||
| Recruiting |
NCT06283589 -
The SEAPORT 1 Study: Evaluation of the Safety and Tolerability of INZ-701 in Adults With End-Stage Kidney Disease Undergoing Hemodialysis
|
Phase 1 | |
| Completed |
NCT04195906 -
Phase 3 Study of SNF472 for Calciphylaxis
|
Phase 3 | |
| Recruiting |
NCT02635373 -
European Calciphylaxis Registry Network
|
N/A | |
| Recruiting |
NCT05018221 -
Better Evidence and Translation for Calciphylaxis
|
Phase 3 |